RecruitingNCT06937034
Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease
Observational Retrospective CoHort Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease
Sponsor
AbbVie
Enrollment
2,000 participants
Start Date
Apr 14, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Main objective of this study is to describe the evolution of infusion settings (base, high and low infusion rates) of foslevodopa/foscarbidopa subcutaneous infusion (LDp/CDp) at different timepoints in the treatment of advanced Parkinson's disease (aPD) as captured in ONE-CRM.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- \- Diagnosed with levodopa-responsive idiopathic Parkinson's Disease prescribed on LDp/CDp CSCI in routine clinical practice who have consented to be enrolled in the AbbVie Patient Support Program.
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06937034
Related Trials
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
NCT0207113484 locations
Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study
NCT072169765 locations
Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG)
NCT073860151 location
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT0717431066 locations
Imaging Depression in Parkinson's Disease
NCT064029551 location